Sign up to save your podcasts
Or
Share Pfizer's Evolving Landscape: Analyzing the 2025 Outlook for Pharma Giant's Stock
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pfizer's Evolving Landscape: Analyzing the 2025 Outlook for Pharma Giant's Stock
As of today, March 21, 2025, Pfizer's stock price is $26.21 per share. This price reflects a slight dip from the day's high of $26.50 and a low of $26.08. The trading volume for Pfizer stock on this day was 42,522,707 shares, which is significantly higher than the average trading volume of 9,156,000 shares over the past three months.
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion. This includes the expectation of revenues from COVID-19 products, which are expected to be largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024[2]. The company also expects full-year 2025 adjusted diluted earnings per share (EPS) to be in the range of $2.80 to $3.00, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance[2].
Analysts have varied price targets for Pfizer stock, with some predicting a range of $15.16 to $43.70 for 2025, indicating high volatility[1]. Another forecast suggests a price range of $31.12 to $31.61 by the end of 2025, indicating steady growth[1]. A more optimistic forecast by PandaForecast anticipates sustained growth, with the stock potentially reaching $40.15 by the end of 2025[1].
The company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, underpins the cautiously optimistic outlook for Pfizer's stock. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories[1].
Overall, Pfizer's stock performance is influenced by a combination of recent news, analyst updates, and the company's financial guidance. The current stock price and trading volume indicate a dynamic market environment, with potential for continued growth driven by Pfizer's robust product portfolio and strategic initiatives.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion. This includes the expectation of revenues from COVID-19 products, which are expected to be largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024[2]. The company also expects full-year 2025 adjusted diluted earnings per share (EPS) to be in the range of $2.80 to $3.00, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance[2].
Analysts have varied price targets for Pfizer stock, with some predicting a range of $15.16 to $43.70 for 2025, indicating high volatility[1]. Another forecast suggests a price range of $31.12 to $31.61 by the end of 2025, indicating steady growth[1]. A more optimistic forecast by PandaForecast anticipates sustained growth, with the stock potentially reaching $40.15 by the end of 2025[1].
The company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, underpins the cautiously optimistic outlook for Pfizer's stock. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories[1].
Overall, Pfizer's stock performance is influenced by a combination of recent news, analyst updates, and the company's financial guidance. The current stock price and trading volume indicate a dynamic market environment, with potential for continued growth driven by Pfizer's robust product portfolio and strategic initiatives.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
View all episodes
By Inception Point AiAs of today, March 21, 2025, Pfizer's stock price is $26.21 per share. This price reflects a slight dip from the day's high of $26.50 and a low of $26.08. The trading volume for Pfizer stock on this day was 42,522,707 shares, which is significantly higher than the average trading volume of 9,156,000 shares over the past three months.
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion. This includes the expectation of revenues from COVID-19 products, which are expected to be largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024[2]. The company also expects full-year 2025 adjusted diluted earnings per share (EPS) to be in the range of $2.80 to $3.00, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance[2].
Analysts have varied price targets for Pfizer stock, with some predicting a range of $15.16 to $43.70 for 2025, indicating high volatility[1]. Another forecast suggests a price range of $31.12 to $31.61 by the end of 2025, indicating steady growth[1]. A more optimistic forecast by PandaForecast anticipates sustained growth, with the stock potentially reaching $40.15 by the end of 2025[1].
The company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, underpins the cautiously optimistic outlook for Pfizer's stock. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories[1].
Overall, Pfizer's stock performance is influenced by a combination of recent news, analyst updates, and the company's financial guidance. The current stock price and trading volume indicate a dynamic market environment, with potential for continued growth driven by Pfizer's robust product portfolio and strategic initiatives.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion. This includes the expectation of revenues from COVID-19 products, which are expected to be largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024[2]. The company also expects full-year 2025 adjusted diluted earnings per share (EPS) to be in the range of $2.80 to $3.00, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance[2].
Analysts have varied price targets for Pfizer stock, with some predicting a range of $15.16 to $43.70 for 2025, indicating high volatility[1]. Another forecast suggests a price range of $31.12 to $31.61 by the end of 2025, indicating steady growth[1]. A more optimistic forecast by PandaForecast anticipates sustained growth, with the stock potentially reaching $40.15 by the end of 2025[1].
The company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, underpins the cautiously optimistic outlook for Pfizer's stock. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories[1].
Overall, Pfizer's stock performance is influenced by a combination of recent news, analyst updates, and the company's financial guidance. The current stock price and trading volume indicate a dynamic market environment, with potential for continued growth driven by Pfizer's robust product portfolio and strategic initiatives.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI